H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update

finance.yahoo.com/news/h-c-wainwright-reaffirms-buy-131838490.html

In This Article:
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best CRISPR stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s supplemental update to its Phase 1 CTX310 trial findings, H.C. Wainwright reaffirmed its Buy rating and $65 price target on the company on June…

This story appeared on finance.yahoo.com, 2025-07-03 13:18:38.
The Entire Business World on a Single Page. Free to Use →